Company Overview
Our Science
- Our Science
- Posters & Publications
Clinical Pipeline
- Clinical Pipeline
- Clinical Trials
Investors & Media
Contact
- Contact
- Patient Contact
Follow Us
- LinkedIn
- X
- Facebook
- Youtube
- Sign Up for Updates

Company Overview

Company Overview Leadership Team Corporate Governance Partnering Career

Our Science

Our Science Posters & Publications

Clinical Pipeline

Clinical Pipeline Clinical Trials

Investors & Media

Investors & Media Press Releases ASX Announcements SEC Filings In the News & Media Events Presentations Analyst Reports Financial Reports FAQ

Contact

Contact Patient Contact

Follow Us

LinkedIn X Facebook Youtube Sign Up for Updates

Press releases.

Immutep to Present Eftilagimod Alpha Clinical Development Update and New Data from Ongoing Melanoma Study

April 2, 2019

Company Overview
Leadership Team
Corporate Governance
Partnering
Career

Our Science
Posters & Publications

Clinical Pipeline
Clinical Trials

Investors & Media
Press Releases
ASX Announcements
SEC Filings
In the News & Media
Events
Presentations
Analyst Reports
Financial Reports
FAQ

Contact
Patient Contact

Australian Investors/Media:

Eleanor Pearson, Sodali & Co.
Ph: +61 2 9066 4071;
eleanor.pearson@sodali.com

US Investor Relations
Ph: +1 (631) 318-4000
chris.basta@immutep.com

© 2025 Immutep. All rights reserved.

Immutep Limited
Level 32, Australia Square
264 George Street
SYDNEY NSW 2000
AUSTRALIA

Ph: +61 2 8315 7003
Fax: +61 2 8569 1880
enquiries@immutep.com

Imprint
Privacy Policy
Terms of Use

© 2025 Immutep. All rights reserved.

© 2025 Immutep. All rights reserved.

Imprint
Privacy Policy
Terms of Use